Development of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration During Anti–Vascular Endothelial Growth Factor Treatment

Cho, Han Joo; Yoon, Wontae; Yoon, Ji-Hyun; Na, Seung Kwan; Lee, Ji‐Hyun; Kim, Jaemin; Kim, Chul Gu; Kim, Jong Woo

doi:10.1016/j.ajo.2021.07.026

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PED definition used in this study was in line with that of our previous investigations and other clinical trials 14 – 16 , i.e., RPE elevation > 400 µm in width and > 75 µm in height or RPE elevation > 200 µm in vertical height. Furthermore, based on the SD-OCT findings, PED was classified as fibrovascular, when there was moderately reflective space adherent under the surface of the PED, or serous, when the PED was optically clear 15 , 17 .…”

Section: Methodsmentioning

confidence: 61%

“…There is evidence regarding an association between smaller CNV lesions and better visual acuity outcomes in several phase 3 trials 24 , 25 . Furthermore, smaller CNV areas were associated with a decreased risk of exudative recurrence, particularly IRF development, during anti-VEGF treatment 26 . In addition to these lines of evidence regarding the favorable prognosis of smaller CNV lesions, our results suggest that during anti-VEGF treatment, consideration of lesion size could be a predictor for recurrence and can assist in deciding the treatment regimen after the loading injections.…”

Section: Discussionmentioning

confidence: 92%

“…Particularly, PED at baseline was more likely to cause recurrence and activity when shifting from a fixed dosing regimen to a flexible dosing regimen 12 . More recently, it was reported that a higher PED height increases the risk of IRF development during anti-VEGF treatment 26 . Hence, neovascular AMD with fibrovascular PED should be monitored cautiously.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission

Cho

Jeon

Yoon

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

We investigated the characteristics of neovascular age-related macular degeneration (AMD), which rarely recurs after initial remission. This study retrospectively analyzed 392 neovascular AMD patients treated with anti-vascular endothelial growth factor (VEGF). All patients received three monthly loading doses of anti-VEGF injections, followed by a pro re nata (as needed) regimen for 24 months. The baseline characteristics associated with the odds of having no recurrence within 24 months were evaluated using multivariate modeling. After the initial three loading injections over 24 months, 58 (14.8%) eyes showed no exudative recurrence and did not require additional anti-VEGF injections. These patients without exudative recurrence had significantly better best-corrected visual acuity (P = 0.003) and lower central subfoveal thickness (P = 0.035) at 24 months than those with exudative recurrence. Additionally, the incidence of macular atrophy was significantly lower in the former than in the latter (8.6% vs. 21.9%; P = 0.020). Multivariate analysis revealed that younger age (odds ratio [OR], 0.901; P = 0.033), smaller lesion size (OR, 0.589; P = 0.016), and absence of fibrovascular pigment epithelial detachment (PED) (OR, 1.349; P = 0.028) were associated with higher odds of no recurrence during follow-up. Approximately 15% of the neovascular AMD patients showed no exudative recurrence after initial remission during the 24-month follow-up. The infrequent recurrence after initial remission correlated with younger age, smaller lesion size, and absence of fibrovascular PED.

show abstract

Section: Methodsmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission

Cho

Jeon

Yoon

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although there are pharmacological treatments for wet AMD available and there are different types of drugs that are being proposed for the management of the disease, there is no ideal treatment available for AMD yet. However, the gold standard treatment proposed for patients with AMD is based on limiting the function of the vascular endothelial growth factor (VEGF) [ 18 , 19 , 20 ] via intravitreal injection of anti-VEGF molecules, which were found to be effective in avoiding the loss of visual function and stabilizing disease progression [ 18 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. There are currently only three drugs that contain anti-VEGF molecules approved by the United States Food and Drug Administration (FDA) for the treatment of AMD.…”

Section: Amd Signs and Symptomsmentioning

confidence: 99%

Therapeutic Approaches for Age-Related Macular Degeneration

Galindo

Blanco-Llamero

Ana

et al. 2022

IJMS

View full text Add to dashboard Cite

Damage to the retinal pigment epithelium, Bruch’s membrane and/or tissues underlying macula is known to increase the risk of age-related macular degeneration (AMD). AMD is commonly categorized in two distinct types, namely, the nonexudative (dry form) and the exudative (wet form). Currently, there is no ideal treatment available for AMD. Recommended standard treatments are based on the use of vascular endothelial growth factor (VEGF), with the disadvantage of requiring repeated intravitreal injections which hinder patient’s compliance to the therapy. In recent years, several synthetic and natural active compounds have been proposed as innovative therapeutic strategies against this disease. There is a growing interest in the development of formulations based on nanotechnology because of its important role in the management of posterior eye segment disorders, without the use of intravitreal injections, and furthermore, with the potential to prolong drug release and thus reduce adverse effects. In the same way, 3D bioprinting constitutes an alternative to regeneration therapies for the human retina to restore its functions. The application of 3D bioprinting may change the current and future perspectives of the treatment of patients with AMD, especially those who do not respond to conventional treatment. To monitor the progress of AMD treatment and disease, retinal images are used. In this work, we revised the recent challenges encountered in the treatment of different forms of AMD, innovative nanoformulations, 3D bioprinting, and techniques to monitor the progress.

show abstract

Factors associated with the development of exudation in treatment-naive eyes with nonexudative macular neovascularization

Cho,

Kim,

Kim

et al. 2024

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Development of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration During Anti–Vascular Endothelial Growth Factor Treatment

Cited by 8 publications

References 28 publications

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission

Therapeutic Approaches for Age-Related Macular Degeneration

Factors associated with the development of exudation in treatment-naive eyes with nonexudative macular neovascularization

Contact Info

Product

Resources

About